Menu
ÚHKT

Impaktované publikace

[1]

Machova Polakova, K.; Zizkova, H.; Zuna, J.; Motlova, E.; Hovorkova, L.; Gottschalk, A.; Glauche, I.; Koblihova, J.; Pecherkova, P.; Klamova, H.; Stastna Markova, M.; Srbova, D.; Benesova, A.; Polivkova, V.; et al.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

[rok vydání 2020, impact factor 11.528 ]

[2]

Polivkova, V.; Benesova, A.; Zizkova, H.; Koblihova, J.; Curik, N.; Motlova, E.; Klamova, H.; Salek, C.; Machova Polakova, K.

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

[rok vydání 2021, impact factor 11.528 ]

[3]

Curik, N.; Polivkova, V.; Burda, P.; Koblihova, J.; Laznicka, A.; Kalina, T.; Kanderova, V.; Brezinova, J.; Ransdorfova, S.; Karasova, D.; Rejlova, K.; Bakardjieva, M.; Kuzilkova, D.; Kundrat, D.; Linhartova, J.; Klamova, H.; Salek, C.; Klener, P.; Hrusak, O.; Machova Polakova, K.

Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining

[rok vydání 2021, impact factor 6.244 ]

[4]

Jaruskova, M.; Curik, N.; Hercog, R.; Polivkova, V.; Motlova, E.; Benes, V.; Klamova, H.; Pecherkova, P.; Belohlavkova, P.; Vrbacky, F.; Machova Polakova, K.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

[rok vydání 2017, impact factor 6.217 ]

[5]

Hrdinova, T.; Toman, O.; Dresler, J.; Klimentova, J.; Salovska, B.; Pajer, P.; Bartos, O.; Polivkova, V.; Linhartova, J.; Machova Polakova, K.; Kabickova, H.; Brodska, B.; Krijt, M.; Zivny, J.; Vyoral, D.; Petrak, J.

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib

[rok vydání 2020, impact factor 5.650 ]

[6]

Machová Poláková, K.; Polívková, V.; Rulcová, J.; Klamová, H.; Jurček, T.; Dvořáková, D.; Žáčková, D.; Pospíšil, Z.; Mayer, J.; Moravcová, J.

Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

[rok vydání 2009, impact factor 3.198]

[7]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 2.806 ]

[8]

Racil, Z.; Razga, F.; Machova Polakova, K.; Buresova, K.; Polivkova, V.; Dvorakova, D.; Zackova, D.; Klamova, H.; Cetkovsky, P.; Mayer, J.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia : the role of different cell types

[rok vydání 2011, impact factor 2.580]

[9]

Rulcová, J.; Zmeková, V.; Zemanová, Z.; Klamová, H.; Moravcová, J.

The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR

[rok vydání 2007, impact factor 2.561]

[10]

Moravcová, J.; Nádvorníková, S.; Zmeková, V.; Michalová, K.; Březinová, J.; Lukášová, M.; Vítek, A.; Hrabánek, J.; Gašová, Z.; Sedláček, P.; Starý, J.

Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML

[rok vydání 2006, impact factor 2.333]

[11]

Moravcová, J.; Zmeková, V.; Klamová, H.; Voglová, J.; Faber, E.; Michalová, K.; Rabasová, J.; Jarošová, M.

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

[rok vydání 2006, impact factor 2.244]

[12]

Machova Polakova, K.; Zmekova, V.; Rulcova, J.; Klamova, H.; Zemanova, Z.; Moravcova, J.

BCR-ABL mutations in chronic myeloid leukemia : not only detection

[rok vydání 2008, impact factor 1.939]

[13]

Razga, F.; Racil, Z.; Machova Polakova, K.; Buresova, L.; Klamova, H.; Zackova, D.; Dvorakova, D.; Polivkova, V.; Cetkovsky, P.; Mayer, J.

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

[rok vydání 2012, impact factor 1.268 ]

[14]

Moravcová, J.; Regner, J.; Moučková, D.; Fišer, K.; Zmeková, V.; Maláčová, R.; Michalová, K.; Klamová, H.

Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.

[rok vydání 2006, impact factor 0.731]